ClinicalTrials.gg
CompletedNCT03972306Updated Jul 8, 2025

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

A Phase 1 interventional study of Ocrelizumab and Ocrelizumab in Multiple Sclerosis (MS), sponsored by Hoffmann-La Roche. Completed at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
15th of 27
134 · median 170
Started
2019
with 2 others
Phase 1
2 of 27
none open now
Registered
8th of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 15th largest by enrollment, is one of 3 that started in 2019, is one of 2 in phase 1, and was the 8th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple sclerosis (MS).

03

Conditions studied

  • Multiple Sclerosis (MS)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Primary Progressive Multiple Sclerosis (PPMS) or Relapsing Multiple Sclerosis (RMS) according to the revised McDonald 2017 criteria (Thompson et al. 2018)
  • Expanded Disability Status Scale (EDSS) score, 0-6.5, inclusive, at screening
  • Absence of relapses for 30 days prior to the screening visit
  • For the dose escalation phase for participants pretreated with ocrelizumab (Group A):

treatment with IV ocrelizumab for at least 1 year prior to screening (i.e., at least two 600-mg doses of ocrelizumab separated by 24 weeks)

  • For women of : agreement to remain abstinent or use acceptable methods during the treatment period and for 6 months after the final dose of ocrelizumab.
  • For female perticipants without :

Women may be enrolled if unless the participant is receiving a hormonal therapy for her menopause or if surgically sterile (i.e., hysterectomy, complete bilateral oophorectomy).

Exclusion criteria

Exclusion Criteria:

  • MS disease duration of more than 15 years for participants with an Expanded Disability Status Scale (EDSS) score \<2.0 at screening.
  • Known presence of other neurologic disorders that may mimic MS, including, but not limited to, the following:
  • History of ischemic cerebrovascular disorders (e.g., stroke, ) or ischemia of the spinal cord
  • History or known presence of Central Nervous System (CNS) or spinal cord tumor (e.g., meningioma,glioma)
  • History or known presence of potential metabolic causes of myelopathy (e.g., untreated vitamin B12 deficiency)
  • History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, human T-lymphotropic virus 1, herpes zoster and myelopathy.
  • History of genetically inherited progressive CNS degenerative disorder (e.g., hereditary paraparesis and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke syndrome)
  • Neuromyelitis optica
  • History or known presence of systemic disorders potentially causing progressive neurologic disease (e.g., lupus, anti-phospholipid antibody syndrome, Sjögren syndrome, Behçet disease, sarcoidosis).
  • History of severe, brain or spinal cord trauma (e.g., cerebral contusion, spinal cord compression
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Group A: Cohorts A1-A4

    Participants (participants pretreated with ocrelizumab) will receive a single injection of subcutaneous (SC) ocrelizumab co-mixed with rHuPH20 in the abdomen. For every new dose level, recruitment will be staggered by enrolling 1 participant in each cohort followed by a 48-hour waiting period to review safety and tolerability data by the Safety Monitoring Committee (SMC) prior to enrolling subsequent participants in the same cohort. Currently, the planned dose escalation steps for patients who enroll in Group A are as follows: * Cohort A1: 40 mg of SC ocrelizumab * Cohort A2: 200 mg of SC ocrelizumab * Cohort A3: 600 mg of SC ocrelizumab * Cohort A4: 1200 mg of SC ocrelizumab

    Drug: Ocrelizumab · Drug: rHuPH20

  • Experimental
    Group A: Cohort A5

    In the non-randomized subphase, participants will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen.

    Drug: Ocrelizumab · Drug: rHuPH20

  • Experimental
    Group A: Cohort AA

    Participants will receive a single 600-mg dose ocrelizumab by intravenous (IV) infusion

    Drug: Ocrelizumab

  • Experimental
    Group B: Cohorts B1-B4

    Ocrelizumab treatment- naive participants will receive a minimum of 3 patients in Cohort B will receive a single SC injection of ocrelizumab co-mixed with rHuPH20 in the abdomen. * Cohort B1: 40 mg of SC ocrelizumab * Cohort B2: 200 mg of SC ocrelizumab * Cohort B3: 600 mg of SC ocrelizumab * Cohort B4: 1200 mg of SC ocrelizumab

    Drug: Ocrelizumab · Drug: rHuPH20

Interventions

  • Administered by subcutaneous Injection

  • Administered by Intravenous (IV) Injection

  • Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab following subcutaneous (SC) administration

    Time frame: At predefined intervals from baseline through end of study (approximately 5 years)

  2. Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab following single IV (intravenous Infusion)administration

    Time frame: At predefined intervals from baseline through end of study (approximately 5 years)

  3. Percentage of participants with adverse events

    Time frame: Baseline to end of study (approximately 5 years)

  4. Percentage of participants with change from baseline in Marked Abnormality in Electrocardiogram (ECG) Parameters

    Time frame: Baseline to end of study (approximately 5 years)

  5. Incidence of local pain at site of injection assessed using Visual Analog Scale (VAS

    Time frame: Baseline to end of study (approximately 5 years)

  6. Incidence of local-injection reaction (ISR) assessed using Local Injection-Site Symptom Assessment (LISSA)

    Time frame: Baseline to end of study (approximately 5 years)

Secondary outcomes

  1. Percentage of Participants with Anti-Drug Antibodies (ADAs) to ocrelizumab

    Time frame: Baseline to end of study (approximately 5 years)

  2. Percentage of Participants with Anti-Drug Antibodies (ADAs) to rHuPH20

    Time frame: Baseline to end of study (approximately 5 years)

07

Study locations

18 sites
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • The NeuroMedical Clinic of Central Louisiana
    Alexandria, Louisiana 71301, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • John Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis
    Owosso, Michigan 48867, United States
  • Washington Univ School of Med
    St Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Cleveland Clinic Mellen Center
    Cleveland, Ohio 44195, United States
  • UC Health Neurology
    Dayton, Ohio 45417, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Neurology Clinic PC
    Cordova, Tennessee 38018, United States
  • University of Texas at Houston
    Houston, Texas 77030, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
08

References and documents

Publications

  • Newsome SD, Goldstick L, Robertson DS, Bowen JD, Naismith RT, Townsend B, Figueiredo C, Kletzl H, Giraudon M, Bortolami O, Zecevic D, Giacobino C, Clinch S, Shen YA, Deol-Bhullar G, Bermel RA. Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. Ann Clin Transl Neurol. 2024 Dec;11(12):3215-3226. doi: 10.1002/acn3.52229. Epub 2024 Oct 26. PubMed 39460719 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jun 2025, 69 months.

Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's 69 months is above that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2019
First posted
Jun 3, 2019
StartActual
Aug 12, 2019
Primary completionActual
Jun 3, 2025
CompletionActual
Jun 3, 2025
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03972306
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 3, 2019
Start date
Aug 12, 2019
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025
Last update
Jul 8, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion